Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolebrutinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK known ✓ | Q06187 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | TEC | P42680 | 2/20 | 1.00 |
| ▸ | CD69 | Q07108 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.77 |
| ▸ | LCK | P06239 | 1/20 | 0.77 |
| ▸ | FYN | P06241 | 1/20 | 0.77 |
| ▸ | YES1 | P07947 | 1/20 | 0.77 |
| ▸ | LYN | P07948 | 1/20 | 0.77 |
| ▸ | HCK | P08631 | 1/20 | 0.77 |
| ▸ | SRC | P12931 | 1/20 | 0.77 |
| ▸ | CSK | P41240 | 1/20 | 0.77 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.77 |
| ▸ | BLK | P51451 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolebrutinib SCHEMBL18285624 | 1.00 | BTK (1.00) | BTKEGFRTECCD69RIPK2 | |
| Tolebrutinib SCHEMBL29564612 | 1.00 | BTK (1.00) | BTKEGFRTECCD69RIPK2 | |
| Tolebrutinib SCHEMBL18285621 | 1.00 | BTK (1.00) | BTKEGFRTECCD69RIPK2 | |
| SCHEMBL18644879 | 0.94 | BTK (0.89) | BTKEGFRTECCD69RIPK2 | |
| SCHEMBL18644867 | 0.93 | BTK (0.88) | BTKEGFRTECCD69RIPK2 | |
| SCHEMBL18644873 | 0.93 | BTK (0.88) | BTKEGFRTECCD69RIPK2 | |
| SCHEMBL18644866 | 0.93 | BTK (0.87) | BTKEGFRTECCD69RIPK2 | |
| SCHEMBL18644669 | 0.93 | BTK (0.86) | BTKEGFRTECCD69RIPK2 | |
| SCHEMBL18644876 | 0.93 | BTK (0.86) | BTKEGFRTECCD69RIPK2 | |
| SCHEMBL18644865 | 0.92 | BTK (0.85) | BTKEGFRTECCD69RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282777-A1 | Methods of Making Tolebrutinib | PRINCIPIA BIOPHARMA INC. (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4547249-A1 | THERAPEUTIC TYROSINE KINASE INHIBITORS FOR MULTIPLE SCLEROSIS AND MYASTHENIA GRAVIS | Principia Biopharma Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024137604-A1 | DRUG FORMULATIONS OF (R)-L-(L-ACRYLOYLPIPERIDIN-3-YL)-4-AMINO-3-(4- PHENOXYPHENYL)-1H-IMIDAZO[4,5-C]PYRIDIN-2(3H)-ONE | GENZYME CORPORATION (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024006406-A1 | THERAPEUTIC TYROSINE KINASE INHIBITORS FOR MULTIPLE SCLEROSIS AND MYASTHENIA GRAVIS | GENZYME CORPORATION (US) | 2024-01-04 | — | — | WO | disclosed |
| CN-115348862-A | Therapeutic tyrosine kinase inhibitors for Relapsing Multiple Sclerosis (RMS) | 建新公司 | 2022-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282777-A1 | Methods of Making Tolebrutinib | ABL1, JAK2, ALK | BTK 29/4885EGFR 164/4885TEC 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.